Ka hanaʻana i nā meaʻehā nuclec acid amplecification eʻike i ka sers-cev-2 maʻAitiopa

Mahalo iāʻoe no ka kipaʻana i ke'ano.com. Ke hoʻohana neiʻoe i kahi polokalamu kele pūnaewele me ke kākoʻo CSS palena. No kaʻike maikaʻi loa, ke noi nei mākou e hoʻohanaʻoe i kahi mea hoʻohana hou (a iʻole hōʻole i keʻano hoʻololi i ka Pūnaewele Pūnaewele). Eia kekahi, e hōʻoia pono i ke kākoʻo o ka home, hōʻike mākou i ka pūnaewele me kaʻole o ka styles a me ka javascript.
E hōʻike i kahi carousel oʻekolu mau kiʻi i hoʻokahi manawa. E hoʻohana i nā pihi a me nā pihi ma mua e neʻe ai ma nā papaʻekolu i ka manawa, a iʻole e hoʻohana i nā pihi slider i ka hopena e neʻe ai ma kahi manawa.
Mai ka maʻiʻo 2019 coronavirus (Covid-19) i waho, he nui o nā hōʻike uila Acplections ACHCAL ʻOiai ua ulu kokeʻia nā hōʻike he nui a hoʻopiliʻia i nā hōʻike hōʻikeʻo nā exgnostic,ʻaʻole i loiloiʻia nā hana o kēia mau hoʻokolohua. No laila, ke nānā nei kēia noiʻi e loiloi i ka hana o ka hana o ka Abbott Sars-COV-2, Daan Genest e hoʻohana ana i keʻano kiko'ī (CRS). Ua alakaʻiʻia ke aʻoʻana ma ke kula olakino Atiotian Chance (EPHI) mai 1 a hiki i 30 mau makahikiʻo ka lā o ABBATT DNA O 164 specimens, 59.1% maikaʻi a maikaʻi a 40.9% i maikaʻiʻole no nā crs. ʻO Sansure biotech positivity ua haʻahaʻa loa ia i hoʻohālikelikeʻia i nā crs (p <0.05). ʻO Sansure biotech positivity ua haʻahaʻa loa ia i hoʻohālikelikeʻia i nā crs (p <0.05). Положительные рые ana ʻO nā hopena maikaʻi loaʻo Sansure biotech i hoʻohālikelikeʻia i nā crs (p <0.05).与 crs 相比 andisher Boutech) 阳性率显着较低 (p <0.05).与 crs 相比 andisher Boutech) 阳性率显着较低 (p <0.05). У ilima Uaʻoi aku ka liʻiliʻi o ka biotech biotech i nā hopena maikaʻi i hoʻohālikelikeʻia i nā crs (p17,05).ʻO kaʻae holoʻokoʻa o nā loiloiʻehāʻehāʻo 96,3-100% i hoʻohālikelikeʻia i nā CRS. Ma kahi o ka helu haʻahaʻa haʻahaʻa haʻahaʻa o ka waiwaiʻo Buitter Biotech Asseay,ʻo ka hana o nā mea waiwai he nui aʻe. E like me ia,ʻo ia ka Buitehi Biotech [ka noiʻi wale nō ʻO ka hopena, pono e noʻonoʻo hou i nā noiʻi hou e loiloi i nā waiwai i nā'ōlelo hoʻopiʻi kūpono.
ʻO ka hōʻikeʻana o ka hōʻikeʻana o ka huiʻana o ka World Health Organization (ʻo wai) hoʻolālā hoʻolālā no Coronavirus maʻi 2019 (Covid-19). ʻO ka mea e aʻo ana i nā'āina e pono ai e kūkulu i ka hiki ke hoʻomaikaʻi i ka hoʻomākaukauʻana, ka hoʻokele kālā kūpono, ka hoʻokele maikaʻiʻana i nā pilikia olakino olakino. Hōʻike kēia i ka hana o ka hana o ke ala e hōʻike ana i ka maʻi a me ka epideminilogy o nā mea i loaʻa a me ka paleʻana i ko lākou mau luna
ʻO keʻano o ka maʻi o Covid-19 he mauʻike maʻi maʻi lapaʻau a me nā maʻi lapaʻau pilikino Mai ka wā i hōʻikeʻia ai ka coot-19 i hōʻikeʻia ma Wuhan, Kina, he nui nā hōʻike a Acplatic ACICCTION ACHPICIFIPTION (Nats) i kūkuluʻia a puni ka honua. Ua hoʻohanaʻia ka mea maoli i keʻano o ka hanaʻana i ka hopena o ka reaction (RTR-PCR) i kahiʻano maʻamau a me keʻano maʻamau no ka maʻi maʻamau. ʻO ka laweʻana i ka laweʻana i ka mālamaʻana o Sars-Cov-2 i hoʻokumuʻia ma keʻano o ka Bena o N ʻO Genele) iʻikeʻia mai ka maʻi maʻi. Ua manaʻoʻia lākou e lilo i nā wahi nui i loaʻa i nā hōʻailona nui i loaʻa i nā genomes viral no ka mahalo virus4. Ma waena o kēia mau genes, ka rdrp a me nā greees i loaʻa kaʻike loiloi kiʻekiʻe,ʻoiai keʻano o keʻano o ka genentika haʻahaʻa.
ʻO ka hana o nā waiwai o PCR e like me nā mea likeʻole e like me nā mea hou aku e like me nā mea hou aku, nā hana hou a me nā mea hana kiʻi. E like meʻApelila 2020,ʻoi aku ma mua o 48 mau polokalamu diagnostic maiʻeiwa mau'āina i loaʻa i ka mana o nā'āina. Ma Ethiopia,ʻoi aku ma mua o 14 mau hoʻolālā PCR i ka hana o ka PCR-COV-3 ma 26000 a me ka ABOT 8000. Eia kekahi, loaʻa nā hōʻike hōʻike hōʻike PCR ma Dean Gene Genest, Abbott Sars-Ciry, And Sars-COV-COV-BGI TRIT. ʻOiaiʻo RTRT-PCR he mea nui loa, kekahi mau mea maʻi me nā huaʻala maikaʻiʻole ma muli o ka hoʻopiliʻana i nā kope nā kūlana a me nā hana o nā limahana8. Ma kahi o ka hanaʻana a iʻole ka hoʻopiliʻana i nā mea koloheʻole,ʻo Cycle thrresth No laila, ua maopopo iā ia nā hōʻike hōʻike PCR i nā mea lawe hewa, e hikiʻole iā lākou ke hoʻokaʻawale i waena o nā mea hana viral maoli aʻaʻole hiki ke hōʻikeʻia nā mea hana No laila, he mea nui ia e loiloi i ka hana diagnostic e hoʻohana ana i nāʻano maʻamau ma kā mākou hoʻonohonohoʻana. ʻOiai he nui nā uku eʻae i loaʻa ma ke keʻena olakino nui (ePHI) a ma nā'āina'ē aʻe,ʻaʻohe mea loiloi o ko lākou hana ponoʻana. No laila, e noi ana kēia noiʻi e loiloi i ka hana hoʻohālikelike o kaʻoihana i loaʻa i nā mea nānā-cart-2 e ka hoʻohanaʻana i nā kiʻi kiʻi crtical.
ʻO ka huina o 164 mau mea komo me nā mea i manaʻoʻiaʻo Covid-19 i kauʻia ma kēia aʻoʻana. ʻO ka hapa nui o nā hiʻohiʻona mai nā keʻena mālama (118/164 = 72%),ʻoiai ke koena 46 Ma waena o nā poʻe komoʻole i mālamaʻia ma ke kikowaena, 15 He kanakolukumamākolu (56.7.7%) nā kāne, aʻo keʻano (± SD
Ma kēia noiʻi, maikaʻi a maikaʻiʻole i nā makanaʻehā no nā hoʻokolohuaʻehā no ka covid-19 i hoʻoholoʻia. No laila,ʻo nā kumukūʻai maikaʻi o ka abat-cev-2 assay, daan guity ʻO ka papa kuhikuhi kūpono a maikaʻiʻole a maikaʻiʻole (CRS) he 97 (59.1%) a me 67 (40.9%. I kēia noiʻi, ua hoʻokumuʻia ka weheweheʻana o nā CRS i ka RRS i ka Rula e loaʻa ana i nā hopena hōʻike heʻehā a keu paha.
Ma kēia noiʻi,ʻike mākou i kahi kuʻikahi maikaʻiʻole (NPA) o 100% (95% CI 94.6-100 Ua hōʻike aku ka loiloi biotechnology biotechnology i kahi ppa o 93.8% (95% ci 87.2) a me ka 95% ci 96.6-99.999. I ka hoʻohālikelikeʻana,ʻaeʻia i waena o ka SERS-Cov-2 BGi Assy a me ka Assaut Chtech 2019-NCOV a me 96,3% a me 96
ʻO ka cheen's Kappa e pono ai kaʻaeʻana ma waena o CRS a me Abbot Sars-Cov-2 mau hualoaʻa e kūlike (K = 1.00). Pēlā nō hoʻi,ʻikeʻia nā waiwai o Coheen's Kappa e Daan Gene 2019-NCOV, a me Sansure Buitech 2019-Ninv. Ma kēia loiloi hoʻohālikelike, ka hōʻike hōʻike chi-square (McNarmar Test) i hōʻikeʻia ka hopena o ka CRSECH 2019-NCOV (1,031).
E like me ka hōʻikeʻia ma Fig.1 ka pakeneka o ka waiwai o ka ct haʻahaʻa (<20 ct) o Abbot Sars-cot-2.6) 1 ka pakeneka o ka waiwai o ka ct haʻahaʻa (<20 ct) o Abbot Sars-cot-2.6)E like me ka hōʻikeʻia ma Fig.1, 1. Проحнгракая Nailopae Nā Pacидео по Nokiaзотоло про "(0 20 Ct) сзасоличие Ct) 1, ka pakeneka o ka waiwai o ka ct haʻahaʻa haʻahaʻa (<20 ct) i hōʻikeʻia no ka helu o ka ct-2,3,6 3.2%.如 图 1所示, Abbott Bares-2 检测 (结合 ct ct 检测 n检测) orft 检测和) 基因最低) 百分比为为) orfv "9为 (百分比为 ct) 的 百分比为 3.2%. E like me ka hōʻikeʻana ma ke kiʻi 1,ʻo ka helu o ka pakeneka haʻahaʻa haʻahaʻa Как показа на На рисено sobpебоцие Онна orf1a / B В исовани Resensure Boutech (blancheva blatech kanv wallpaper E like me ka hōʻikeʻana ma ke kiʻi 1, ka Sen-Cov-2 assauy Процне значенкий (<20% .Ka .Ka. Росонковииии ʻO ka pakeneka o nā waiwai (<20 ct) he 50.3%, aʻo ka pakeneka o nā waiwai ct kiʻekiʻe (36-40 ct) he 3.2%.ʻO ka poʻeʻo Abbot Sars-Cov-2 B e hōʻike i nā waiwai CT i hoʻopaʻaʻia ma luna o 30. Ma ka lima'ē aʻe, ma luna o ka BIRS BERS-Cov-2 assay Orf1a / B Guty he nui BT Ma ka lima'ē aʻe, ma luna o ka BIRS BERS-Cov-2 assay Orf1a / B Guty he nui BT СшРгойВИ Hale Аны Houlima-Black-2 гаениоеото CH (> Ma kaʻaoʻao'ē aʻe, ma ka nānāʻana o BGI Sars-Cov-2 Gene orf1a / B i kahi helu CT kiʻekiʻe ((36 CT)另 一 (在 bgi Sars-cov-2 检测中, orf1a / b 图 ct). Ma ka lima 'ē aʻe, ma BGi Sars-Criv-2 Deviction СшРгойТороны Houke-b10 -изкив МИ.) Ma ka lima'ē aʻe, ma ka waihona BGi-CGI-CGI-2 ka nānāʻana, ka pakeneka o Orf1a / B he 4% (FIG). 1).
Ma kēia noiʻi, lawe mākou 164 Nasopharyngeal. No nā mea nalowale,ʻo Rna Hoʻonāʻiʻia a me nā'olini a me ka'ū'īʻana ma keʻano o nāʻano hana a me nā māka i hāʻawiʻia e ka mea hana ma ka pono.
Hōʻike kēia noiʻi i ka hōʻikeʻana o Abbott no Sars-Cov-2 mau mea like me nā crs, me 100% maikaʻi, a me ka maikaʻiʻole. ʻO kaʻikepiliʻo Cohan's Kappa he 1.00, e hōʻike ana i kaʻae piha piha me CRS. ʻO kahi noiʻi likeʻole e ke Kulanui o Wakinekona i ka US iʻikeʻia e pili ana i ka Sister-COV-2) 11.ʻO ka'ōnaehanaʻo Abbott Sen-COV-2 i loaʻa i kaʻike i hoʻohuiʻia i kaʻike likeʻole o ka N a me RDRP GRES, e like me nāʻano maʻamauʻelua. ʻO ka noiʻiʻana ma Vieenna, ua hōʻikeʻiaʻo Austria i ka nui o nā helu hōʻailona nui a me ka nānāʻana i nā hopena liʻiliʻi e liʻiliʻi ai. No laila,ʻo ka pāʻani kūpono a ABBot no ka SERS-COV-2 e pili ana i kahi'ōnaehana iʻikeʻia (0.5 ML)
Ua hōʻikeʻia kā mākou hopena e hōʻike ana kaʻike o kaʻike o ka hōʻike daan genetic e like me nā crs. Ke kūlike nei kēia me ka hoʻopaʻa inoaʻana ma ke Kulanuiʻo Ahuinan, China, a me ka'ōlelo a ka mea hana maikaʻi. ʻOiai ke hōʻikeʻana i nā hopena o nā hopena kūpono, he wahaheʻe kekahi mauʻano maʻamau ma hope o ka hoʻihoʻiʻana i ka Yolute Sels-cirst Hōʻike kēia i nāʻano likeʻole ma nā hopena ma waena o nāʻano likeʻole. Eia nō naʻe, ma ke aʻoʻana i laweʻia ma Kina15,ʻo ka hopena o ka mea waiwaiʻo Dean Gen Gene Stuay Eia nō naʻe, ma ke aʻoʻana i laweʻia ma Kina15,ʻo ka hopena o ka mea waiwaiʻo Dean Gen Gene Stuay Тем не не3, Исследнтии WAа ииатаенго та ктбовчонгаебовчонгаель نشاطات NaHieki | Eia nō naʻe, ma kahi noiʻi ma Kina15,ʻo Dana Genentis e like me ka hopena o Dean Gen Gen Genentis然而, 在中国进行 在中国进行гра 的 结果与其实验室定义 的 参考检测相比有显着差异 (Ра5).然而, 在中国进行 在中国进行 大安基因检测 大安基因检测гра 结果与其实验室定义ото 参考检测相比有显着差 © 大安基因检测参考检测相比有显着差 参考检测相比有显着差 (0.05 Фоднакннавни, Lokбкуннном в Та Та nahoеТИТа сзаетаемэгакнемогаонне Блабоüтторным тотом. Eia naʻe, ma kahi aʻo ma China15,ʻoi aku ka hopena o nā hōʻike o Daman o Dane's Genetic Exchange (P <0.05) i hoʻohālikelikeʻia i kāna hōʻike hōʻike.Hiki paha i kēia mea hoʻowahāwahā ma muli o keʻano o ka hōʻike hōʻike eʻike ai i ka mālamaʻana i ka Sers-2, a he mea nui paha e hoʻoholo i ke kumu.
Eia kekahi, ua loiloi kā mākou aʻoʻana i ka hana hoʻohālikelike o ka SERS-COV-2 BGI ). = 98.8%). Ua hōʻikeʻo Cohan's Kappa i hōʻike maikaʻi i kaʻae maikaʻi (K = 0.975). Nā haʻawina ma nā Netherlands16 a me Kina15 i hōʻikeʻia e nā hopena kūlike. ʻO ka hōʻikeʻo Sars-Cov-2 BGI he hoʻokahi Genent Genent ʻOiai ke kuʻikahi kūpono kūpono me kā mākou mau hopena kuhikuhi, ua hala ka loiloi iʻelua mau hiʻohiʻona maikaʻi (1.22%) o ka helu helu. Hiki i kēia ke loaʻa i nā hopena olakino nui loa no nā mea i hoʻounaʻia ma nā pae maʻi a me keʻano kaiāulu.
ʻO kekahi loiloi hoʻohālikelike hou i hoʻokomoʻia i kēia noiʻiʻo ia ka mea i hoʻopaʻaʻia i ka biotech ncov-2019 rrt-PCR (RuO) ʻO ka pae kiʻekiʻe o ka pakeneka ma mua o 96,3%. Ua hoʻoholoʻia ka ikaika o kaʻaeʻana i ka waiwai o Kappa a ka chen a ka cheen,ʻo 0.925, e hōʻike ana i kaʻae piha me nā CRS. Eia hou,ʻo kā mākou mau hopena e pili ana i nā haʻawina i laweʻia ma ke KulanuiʻAmelika Hui PūʻIa,ʻo Li Li Linghay, China17. ʻOiaiʻoiaiʻo ka mea i hōʻikeʻia ma luna nei, ua hoʻopaʻaʻia ka hōʻike kālā ma luna nei,ʻo ka hōʻikeʻo Chi-Square ʻOiaiʻoiaiʻo ka mea i hōʻikeʻia ma luna nei, ua hoʻopaʻaʻia ka hōʻike kālā ma luna nei,ʻo ka hōʻikeʻo Chi-Square Несмотретитиксикск смка Nхитакие Воазание что Тузультатаа hae ai ʻOiaiʻo kaʻaeʻana o ka statistical Science ma luna nei, ua hōʻikeʻia ka hōʻike chi-square尽管记录了 述良好述良好 的 致性у, 致性尽管尽管 述述 致性 致性 一检验 一检验 一检验 (Malimamaha Kah 检验检验. На на на ноенельходтаке макетакие <0,005). ʻOiai ke hōʻikeʻia nei ka'ōlelo aʻoi aku ka maikaʻi ma mua,ʻo ka hōʻike hōʻike chi-squareʻEono mau hiʻohiʻona (3.66%) iʻikeʻia e pili i nā negatives maikaʻi i hoʻohālikelikeʻia i nā crs (uplplementary papaʻaina 1); He mea nui loa kēia Kākoʻo kaʻikepili i luna aʻe i kēia helu haʻahaʻa haʻahaʻa haʻahaʻa.
I kēia noiʻiʻana, ua hoʻoholoʻia nā waiwai CT no kēlā me kēia mea waiwai a me nā kahua pili i hōʻikeʻia, me ka haʻahaʻa haʻahaʻa haʻahaʻa E pili ana paha kēia hopena i ka'ōnaehana hoʻokūkūʻo Abbot No laila,ʻo ke kiʻi e like me ke kiʻi 1, 87.6% i nā huapalapala o Abbott ma lalo o 20.ʻO kahi helu liʻiliʻi he 20.4. ʻAʻole i kākauʻia nā CT i mua o 30. Ma kahi o ka hoʻohanaʻana o Abbott o ka Chers-Cov-2 Pander Tentitic Testing format ML) 19.
Loaʻa kēia noiʻi i kekahi mau palena: mua,ʻaʻole mākou e loaʻa i nā hana maʻamau /ʻano e like me nā mea hana viral (ree. ʻO ka lua, nā sexmens āpau i hoʻohanaʻia ma kēia noiʻi he mau kīwīʻo Nasopharygeal,ʻoiai ua hoʻopiliʻia nā hopena'ē aʻe i nāʻano hana'ē aʻe, a ua liʻiliʻi ko mākouʻano hoʻohālike.
Ua hoʻohālikelike kēia noiʻi i ka hana oʻehā mau RRT-PCR Asseays no Sars-Cov-2 me ka hoʻohanaʻana i nā mea likeʻoleʻo Nasopharyngeal. Ua kokoke loa nā meaʻike a pau i ka hana i hoʻohālikelikeʻia, me kaʻokoʻa o ka waiwai biotech biotech. Ma waho aʻe, uaʻikeʻia ka wikiwiki o ka helu posithity haʻahaʻa i loko o ka mea kanu biotech i hoʻohālikelikeʻia i nā crs (p17,05). Ma waho aʻe, uaʻikeʻia ka wikiwiki o ka helu posithity haʻahaʻa i loko o ka mea kanu biotech i hoʻohālikelikeʻia i nā crs (p17,05). Ohana lake Того .тесте Sanaup Ma kahi o ka hōʻikeʻana i hōʻikeʻia i ka hōʻike biotech i hōʻike i kahi pakeneka haʻahaʻa haʻahaʻa o nā hopena maikaʻi i hoʻohālikelikeʻia i nā crs (p17 0.05).此外: 与 crs相比, sarire phitethan 检测 的 <(p <0.05).此外: 与 crs相比, sarire phitethan 检测 的 <(p <0.05). Крмено, Ноловои Sansure BounshiSior ималоинительноительноетельвое "p <0,05). Ma kahi o ka waiwai o ka waiwaiʻo Biotech Assy i loaʻa i ka helu positivity haʻahaʻa haʻahaʻa i hoʻohālikelikeʻia i nā crs (p17,05).ʻO ka mālamaʻana iā Biotech Ncov-2019 (Ruo) ka nānāʻana i ka PPA, ʻO ka mea hope loa,ʻo ka mea nāna e koi i ka waiwai
Kūkuluʻia ka hoʻolālā noiʻi hoʻohālikelikeʻana ma nā kula olakino BET BILLIGH, EKA Kololi Sashingpital Center, Milleni Ua hōʻiliʻiliʻia kaʻikepili ma waena o Dekemaba 1 a me 31, 2020.ʻO nā pono olakino no kā lākou noiʻiʻana i keʻano o kaʻoihana ma ke kūlanakauhale. Penei, mau mea kau, e pili ana i ka Abi 7500 a me Abbott m2000 mau mea hana maoli, a i kohoʻia e like me ka nui o nā kaukauʻana ma'Eliopia. Hōʻike Genery, Abbott Sars-Cov-Dest, Sansure Bitech Stuence
ʻO ka ho'āʻoʻana no ka Sar-Cov-2 i hanaʻia mai 1 a 30 December 72 Ua hōʻiliʻiliʻia nā kiʻina Nasopharyngeal i nā mea hōʻiliʻili i hoʻomaʻamaʻaʻia e nā mea hōʻiliʻili i hoʻomaʻamaʻaʻia a hoʻounaʻia iā EPHI i nā'āpana triple. Ma mua o ka hoʻokaʻawaleʻana o ka hoʻopiliʻana o ka nukletic, ua hāʻawiʻia kēlā me kēia hoʻohālike i kahi heluʻike kūʻokoʻa. Hanaʻia ka extractions mai kēlā me kēia hoʻohālike i ka hiki kokeʻana i ka hikiʻana i ka hoʻohanaʻana i nā hana manual a me nāʻano hana hou. No laila, no ka loaʻaʻana o Abbott M2000, 1.3 ML (me ka helu o Abbott DNA Dralte a me X8 mol. ) He'āpana o 96 [92 mau hiʻohiʻona,ʻelua mau mea nānāʻelua a meʻelua mau corrot (NTC) i nā manawaʻelua (NTC) minging. Pēlā nō, no ka hanaʻokoʻa, hoʻohana i nā hiʻohiʻona likeʻole (no ka loaʻaʻana o ka extratial a me ka loaʻa). No laila, ma keʻano o ke kaʻina hana, 140 μL i hoʻohuihuiʻia a laweʻia i ka hoʻohanaʻana i ka quamp vil mika Ua hoʻohuiʻia nā mea i laweʻia aʻikeʻia e hoʻohana ana i ka hoʻohanaʻana i kahi cycoly Abi-Cirmal,ʻo Dan Au Sansuree Bioy.
Hoʻoliloʻia a me ka hoʻomaʻemaʻeʻana o Sars-Cov-2 viral RNA magnetic Bead Booccle e hoʻohana ana iā Abbott DNam ʻAʻole i laweʻia ka hanaʻana o nā hiʻohiʻona a me ka hoʻoponoponoʻana i nā'āpana viral i hoʻohanaʻia e hoʻohana ana i kahi pale i loaʻa i keʻano o ka mea kūʻai aku e hōʻole i ka pronamenid. ʻO ka RNA i hoʻokaʻawaleʻia mai ka protein e ka hoʻokaʻawaleʻana o ka silica,ʻo ia ka silica silf o nā silica (siro2). Hoʻopau ke alaʻo Rinsing i nā pale o nā protein a me nā'ōpala e hana i kahi hopena. ʻO ka rna transparent e hoʻokaʻawaleʻia mai nā micucat micuca Ma ka lima'ē aʻe
ʻO ka hōʻikeʻo Abbot-Tibol-Tib-2 detection Express (Abbott Moolecular, Inc.) Ma kēia Protocol, Sample Ucple Inctivation ma mua o ka hanaʻana i ka wā i hanaʻia ma kahiʻauʻau wai ma 56 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 ° C no 30 Ma hope o ka loaʻaʻana o ka virus i ka hanaʻana,ʻaʻole i hanaʻiaʻo nuclec Account i kahi mea hana abbott m2000 e like me ka mea hana. Ua hanaʻiaʻo Amplification a me kaʻike i ka hoʻohanaʻana i kahi mea hana abbott m2000 rt-PCR, a ua hanaʻia kaʻikeʻelua no ka rdrp a me nā n gense. Rox) a me VIC P (ProPrieTary Dye) no ka nānāʻana a me kaʻikeʻana i nā mana o loko
Hoʻokumuʻia keʻano o keʻano o kēia pahu o kēia pahu ma kahiʻenehana RT-PCR. Ua kohoʻia nā orf1A / B a me N GIN i nā inoa i hoʻopaʻaʻia e Dean General Technology eʻike i nā helu helu helu. ʻO nā kumu mua a me nā mea hoʻopiʻi fluerescent Ua hoʻomākaukauʻia nā hui hope loa a me ka haku e hoʻohuiʻia e ka hoʻohuiʻana iā 5 μ Ua hanaʻia ka Amplification a me kaʻike i ka manawa like ma luna o kahi Abi 750024 Real
Uaʻikeʻia ka orf1a / B a me N GINES i ka hoʻohanaʻana i ka counter biotech ncov-2019 nuklec acid diagnostic kit (2019 nucorescent PCRR). E hoʻomākaukau i nā'ōnaehana kūikawā no kēlā me kēia pahuhopu Genek ma ke kohoʻana i ke kahawai nui no ka orf1a / B BAX Channel no ka N GO GAX CHANT. I kēia kāpena waiwai, ua hoʻohui a me ka Master a me ka Master Ruving Revings: E hoʻomākaukau i ka hana o 30 μl e pili ana i ka heluʻana a me 20 μL Ua hoʻohanaʻiaʻo PCR o PSR i ka Abi 7500005 no ka hoʻohui /ʻike.
ʻO ka hōʻikeʻo Sars-Cov-2 BGI i kahi fluorescent maoli maoli-manawa RRT-PCR no ka maʻi o ka cotom-19. Aia ka'āina i kauʻia ma ka orf1a / B i kahi o ka Sars-Cov-2 Genome,ʻo ia kahiʻano maʻamau. Eia kekahi,ʻo ke kanaka mālama kanaka i ka genent β-actin i hoʻonohonohoʻia i loko o keʻano. Ua hoʻomākaukauʻia ka haku kālā ma ke kāwiliʻana iā 20 μ ʻO kahi Abi 7500 Flierescent Rolscent e hoʻohanaʻia i ka mea hana PCR i hoʻohanaʻia no ka hoʻohuiʻana a me kaʻike. ʻO nā helu uila ACIDIC āpau, holo nā kūlana PC no kēlā me kēia waiwai, a me ka weheweheʻana i nā'ōlelo a nā mea hana hana e like me ka papa hana no ka mea hana no ka mea hana e like me ka papa hana no ka mea hana
Ma kēia hoʻohālikelike hoʻohālikelike,ʻaʻole mākou i hoʻohana i ke ala e pili ana i keʻano kūlana e hoʻoholo ai i ka pakeneka (maikaʻi, maikaʻi loa, a me nāʻano hoʻohālikelike'ē aʻe. Ua hanaʻia kēlā me kēia hoʻohālikelikeʻana me CRS, ma kēia noiʻiʻana i nā CRS i hoʻonohonohoʻia e ka RENU "a ua hoʻoholoʻia ma kahi oʻelua mau hopena hōʻike. Eia kekahi, ma keʻano o ka cody-19 transport,ʻoi aku ka maikaʻi o nā hopena maikaʻiʻole ma mua o nā hopena maikaʻi. No laila, e haʻi aku "maikaʻi" e like me ka hiki ke hiki mai kahi hopena cRs, ma ka liʻiliʻi e pili ana i ka liʻiliʻi o kahi hopena maikaʻi. No laila, i waho o nā hopena hōʻikeʻehā,ʻelua mau hopena hōʻikeʻelua a iʻole nā ​​hopena hōʻike e hāʻawi ai i ka hopena likeʻole i manaʻoʻia he maikaʻi a maikaʻiʻole paha.
Ua hōʻiliʻiliʻia kaʻikepili i ka hoʻohanaʻana i nā palapala hōʻike hōʻike i hoʻonohonohoʻia, nā helu helu a me ka loiloi i hanaʻia e hoʻohana ana i nā helu helu Scetistical Active 23.0 ʻO ka maikaʻi, maikaʻi, a me kaʻaeʻana o ka pakeneka ma ka heluʻana, a ua hoʻohanaʻia ka heluʻo Kappa e hoʻoholo i ke kiʻekiʻe o kaʻaelike o kēlā me kēia. Ua weheweheʻia nā waiwai o Kappa e like me kēia: 0,01 i ka 0.20 no kaʻaeʻana, 0.21-0.9.2.0.9.9.90
Ua loaʻa i ka hoʻomaʻemaʻe i ke kulanui mai ke Kulanui o Addis AdabA a me nā Profister Exctor of Account Of Adioper Health Institution Computer Computer offigote offic ʻO ka helu pili no ka laikini laikiniʻo EPHOSENESSʻo EPHI / Irb-279-2020. Ua hoʻopiliʻia nāʻano hana a pau e like me nā'ōlelo a me nā'ōlelo a me nā'ōlelo o nā kulekele aupuni Atiotian no ka mālamaʻana o Covid-19. Eia kekahi, ua loaʻa kaʻae i kākauʻia iʻikeʻia mai nā poʻe noiʻi a pau ma mua o ke komoʻana i ke aʻoʻana.
Loaʻa i nāʻikepili āpau a iʻole i hoʻopaʻaʻia i kēia noiʻi i hoʻokomoʻia i kēiaʻatikala i paʻiʻia. Ke kākoʻo nei nāʻikepili i nā hopena o kēia noiʻiʻana mai ka mea kākau e pili ana i ka noi kūpono.
World Health Organization. Nā manaʻo no nā mea hōʻike hoʻokolohua hana no nā mea hana hoʻokūkū hana no ka codosed-19: 2020 no Malaki 21 2019.
ʻO Muliouou, ds, pantazaopoulos, i. & gourgoulisoanis, ki covid-19 smart diagnosis i kaʻoihana ulia. ʻO Muliouou, ds, pantazaopoulos, i. & gourgoulisoanis, ki covid-19 smart diagnosis i kaʻoihana ulia.Muliou, ds, ponazaomopoulo, i. a me Gurgullianis, ke kaiaulu kicelistrant: nā mea āpau.Muliou ds, pantazaopoulos i. a me Gurgulynanis i ka hoʻokūkū o CODO-19 ma nā keʻena e hiki ai i ka hana. Ua hōʻoleʻo Adrturnd Referend. Kālāʻoihana. 3, 263-272 (2022).
Mitchell, sl & s zeorge, k. loiloi o ka covid19 itauass. Mitchell, sl & s zeorge, k. loiloi o ka covid19 itauass.Mitchell, sl a me St. George, k.ʻO ka loiloi o ka Covid19 idd State.Mitchelll Sl a St. George K. Relivation o ka Covid19 IDʻo ia i kahi mea waiwai. J. Clinical. Virus. 128, 104429. HTTPS://DOI.org/10.1016/j.jcv.2020.2020.20499 (2020).
Nana. ʻO kaʻikeʻana i ka hana o Coronavirus maʻi 2019 (Covid-19) i nā maʻi maʻi kāne kāne. https://www.who.in.hublications/i/Publications/10665-33950 1 August 2020).
Udgama, B. Et al. Codos-19 maʻi maʻi: nā maʻi a me nā mea hana ho'āʻo. Acs nano 14 (4), 38), 3822-3835 (2020).
Syed s. et al. Ka hoʻokumuʻana o ke kolepa o nā pathologists o ka hikina a me ke kulanui a meʻAmelika Hema o ka papa waena a me kaʻAmelika Hema. Africa. J. Lab. Kālāʻoihana. 9 (1), 1-8 (2020).
ʻO Ethiopuast Institute of First Health Health of Healstry of Health. Interim National Arching a me ke alakaʻi no ke alakaʻiʻana i ka maʻi o ka limahana o Covid-19. https:/2iri.gov.et/image_cornavirus/Phivac_pDf
Woloshin, S., Patel, N. Woloshin, S., Patel, N.ʻO Volosh S., Patel N. a me Kosselheim e like me nā ho'āʻo maikaʻiʻole-maikaʻiʻole no nā mea momona-cev-2 mau hopena a me ko lākou hopena.ʻO Volosh S., Patel N. a me Kesselheim me nā hōʻike maikaʻiʻole e hoʻonāukiuki i ka hoʻonāukiukiʻana a me ka hopena o ka mālamaʻana i ka mālama-COV-2. N. Eng. J. o ka laka. 383 (6), E38 (2020).
Muliou, DS & Gourgoulililis,ʻo nā mea hana maikaʻiʻole-maikaʻi a me nā mea mālama ponoʻole, a me nā mea hoʻokele. Muliou, DS & Gourgoulililis,ʻo nā mea hana maikaʻiʻole-maikaʻi a me nā mea mālama ponoʻole, a me nā mea hoʻokele. Moulouou, Ds and Gourgoundianis, Kik @PaulaPaulaAnoka лучна и Рекециж плаль акейшие перекикы. ʻO Muliouou, ds & gourgoulilitisis,ʻo nā hihia maikaʻi maikaʻi a me nā mea maikaʻiʻole a me ka paleʻana a me ka palekana.Muliu, ds a me Gurgulnianis,ʻo nā mea hewa maikaʻi-maikaʻi a me nā mea maikaʻiʻole o Covid-19: Stateginanies Ua hōʻoleʻo Adrturnd Referend. Kālāʻoihana. 15 (8), 993-1002 (2021).
ʻO Muliuli, ds, ioananis, P. & Konstantinos, G.ʻO ka lāʻau lapaʻau i ka nahele. ʻO Muliuli, ds, ioananis, P. & Konstantinos, G.ʻO ka lāʻau lapaʻau i ka nahele.Muliouou, ds, ioana, p. a me Konstantinos, G. Ke nānā aku i ka lāʻau.Muliou ds, iannis p., a me Konstantinos G. 18 Diagnosis ma nā lumi ulia:ʻaʻole lawa ka ulu lāʻau no nā lāʻau. Kūkaʻi. Kālāʻoihana. J. HTTPS http://doi.org/10.1136/2122119-212219 (2022).
Degli-Angeni, E et al. ʻO ka hōʻoia a me ka hōʻoiaʻana o ka mea hoʻokele a me ka hoʻomaʻamaʻaʻana i ka hana o ka Abbott Daretime Reatime Sars-Cov-2. J. Clinical. Virus. 129, 104474. HTTPS://DOi.org/10.1044
ʻO Morliei, hr, afshar, a, Kalantsmanian, m. ʻO Morliee, HR, hoʻokahi ma AA, KalantSmanian, B.ʻO Morliei, hr, afshar, a, Kalantsmanica, M. Mellaii, hr, afshat, AA, C. rt, FOzLA ʻO Morliee, HR, hoʻokahi ma AA, Kalantsmanian, B.Mllaei hr, afshar aa, KalaheleIran. J. Microbiology. 12 (3), 185 (2020).
ʻO Gourtzer, I. Et al. ʻO nā hopena mua o ka papahana loiloi o ke kaiāulu o waho no kaʻikeʻana i kaʻikeʻana o Sars-COV-2 GENME. J. Clinical. Virus. 129, 104537. HTTPS://DOI.org/10.106/j.JCv.2020.2020.20437 (2020).
Wang, m. et al. Ka loiloi loiloiʻana o ka hopena o ka hopenaʻelima Rort kalepa. anue. 35 (1), E23643 (2021).
Wang b. et al. Ka loiloiʻana iʻehiku mauʻoihana waiwai i loaʻa i nā cars-can-2 rna i nā kits ma china e pili ana i keʻano o ka manawaʻo China. olakino. Kemika. kalepa. Kālāʻoihana. 58 (9), E149-e1433 (2020).
Van Casteren, pb et al. Ka hoʻohālikelikeʻana oʻehiku mau kālā o ka coldercial rt-psrr coovid-19. J. Clinical. Virus. 128, 104412 (2020).
LU, Yu, et al al. Ka hoʻohālikelikeʻana o ka hana diagnostic o nā kime pcsʻelua no kaʻikeʻana i nā maʻi o Sars-COV-2 nuckac acific. J. Clinical. kalepa. anue. 34 (10), E23554 (2020).
Lefart, Pr, Etc. He haʻawina hoʻohālikelike oʻehā mau kalepa a me nā papa inoaʻo ACV. maʻi maʻi. microbiology. Irfect. diss. 99 (1), 115200 (2021).
Abbott molelecule. ABBOTT OUT-WELIM-CERS-COV-2 helu helu i hoʻokomoʻia. https://www.molecular.abbot.abbot/us/Esects/incease: 1-12. (Ma kahi oʻAukake 10, 2020) (2020).
Klein, s. et al. Sars-cov-2 rna e hoʻokaʻawale i nā beads magnettic no ka heleʻana o ka rapid nui nui e ka RT-QPCR a me RTPCR a me RTPCR a me RTPCR. Virt 12 (8), 863 (2020).